文献速递认知障碍与痴呆

临床前阿尔茨海默病纵向Tau-PET的性别差异:一项荟萃分析

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis.
PubMed 文献 · JAMA Neurol · 2025-03-03

该荟萃分析纳入6项纵向老化与AD研究共1376名参与者,评估高Aβ状态下女性性别与tau积累速率的关系。结果发现,在高基线Aβ个体中,女性在颞下回、颞梭状回和外侧枕叶区域tau积累快于男性;在APOEε4携带者中,女性颞下回tau积累也更快。提示AD病理进展存在性别差异,抗Aβ和抗tau治疗时需考虑性别特异性时机。

要点

  • 高Aβ状态下,女性颞下回、颞梭状回和外侧枕叶tau积累快于男性。
  • APOEε4携带者中,女性颞下回tau积累快于男性。
  • AD病理进展存在性别差异,治疗时需考虑性别特异性时机。

核心结论

  • 高Aβ状态下女性tau积累速率快于男性,且APOEε4携带者中女性颞下回tau积累更快。
  • AD病理进展的性别差异提示抗Aβ和抗tau治疗需考虑性别特异性时机。

研究设计与样本

  • 荟萃分析纳入6项纵向老化与AD研究,共1376名参与者(女性761名,55%)。
  • 参与者首次tau扫描平均年龄71.9岁(范围46-93岁),高基线Aβ者401名(29%),APOEε4携带者412名(30%)。
  • 纵向数据收集于2004年11月至2022年5月,分析于2023年8月7日至2024年2月5日完成。
  • 采用混合效应模型提取性别及性别与基线Aβ-PET状态交互与纵向tau-PET的关联估计,并合并进行荟萃分析。

主要发现

  • 高基线Aβ个体中,女性颞下回tau积累快于男性(β = -0.14;95% CI,-0.22至-0.06;P = .009)。
  • 高基线Aβ个体中,女性颞梭状回tau积累快于男性(β = -0.13;95% CI,-0.23至-0.04;P = .02)。
  • 高基线Aβ个体中,女性外侧枕叶tau积累快于男性(β = -0.15;95% CI,-0.24至-0.06;P = .009)。
  • APOEε4携带者中,女性颞下回tau积累快于男性(β = -0.10;95% CI,-0.16至-0.03;P = .01)。

临床怎么用

  • 研究结果提示,在给予抗Aβ和抗tau治疗时,应考虑性别特异性的时机选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alzheimer disease (AD) predominates in females at almost twice the rate relative to males. Mounting evidence in adults without AD indicates that females exhibit higher tau deposition than age-matched males, particularly in the setting of elevated β-amyloid (Aβ), but the evidence for sex differences in tau accumulation rates is inconclusive. OBJECTIVE: To examine whether female sex is associated with faster tau accumulation in the setting of high Aβ (as measured with positron emission tomography [PET]) and the moderating influence of sex on the association between APOEε4 carrier status and tau accumulation. DATA SOURCES: This meta-analysis used data from 6 longitudinal aging and AD studies, including the Alzheimer's Disease Neuroimaging Initiative, Berkeley Aging Cohort Study, BioFINDER 1, Harvard Aging Brain Study, Mayo Clinic Study of Aging, and Wisconsin Registry for Alzheimer Prevention. Longitudinal data were collected between November 2004 and May 2022. STUDY SELECTION: Included studies required available longitudinal [18F]flortaucipir or [18F]-MK-6240 tau-PET scans, as well as baseline [11C] Pittsburgh Compound B, [18F]flutemetamol or [18F]florbetapir Aβ-PET scans. Recruitment criteria varied across studies. Analyses began on August 7, 2023, and were completed on February 5, 2024. DATA EXTRACTION AND SYNTHESIS: In each study, primary analyses extracted estimates for the sex (female or male) and the sex by baseline Aβ-PET status (high or low) association with longitudinal tau-PET using a series of mixed-effects models. Secondary mixed-effects models extracted the interaction estimate for the association of sex by APOEε4 carrier status with longitudinal tau-PET. Study-specific estimates for each mixed-effects model were then pooled in a meta-analysis, and the global fixed effect (β) and total heterogeneity (I2) across studies were estimated. This study is reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. MAIN OUTCOMES AND MEASURES: Seven tau-PET outcomes that showed cross-sectional sex differences were examined across temporal, parietal, and occipital lobes. RESULTS: Among 6 studies assessed, there were 1376 participants (761 [55%] female; mean [range] age at first tau scan, 71.9 [46-93] years; 401 participants [29%] with high baseline Aβ; 412 APOEε4 carriers [30%]). Among individuals with high baseline Aβ, female sex was associated with faster tau accumulation localized to inferior temporal (β = -0.14; 95% CI, -0.22 to -0.06; P = .009) temporal fusiform (β = -0.13; 95% CI, -0.23 to -0.04; P = .02), and lateral occipital regions (β = -0.15; 95% CI, -0.24 to -0.06; P = .009) compared with male sex. Among APOEε4 carriers, female sex was associated with faster inferior-temporal tau accumulation (β = -0.10; 95% CI, -0.16 to -0.03; P = .01). CONCLUSIONS AND RELEVANCE: These findings suggest that sex differences in the pathological progression of AD call for sex-specific timing considerations when administrating anti-Aβ and anti-tau treatments.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Coughlan GT, Klinger HM, Boyle R, et al. Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis. JAMA Neurol. 2025. PMID: 40029638. doi:10.1001/jamaneurol.2025.0013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。